Trial Profile
Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 22 Feb 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Dec 2017 New trial record